To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: FDA Approves Silodosin for the Treatment of Benign Prostatic Hyperplasia
URL: http://www.pslgroup.com/dg/22E6C2.htm
Doctor's Guide
October 9, 2008

NEW YORK -- October 9, 2008 -- The US Food and Drug Administration (FDA) has approved silodosin (Rapaflo) for the treatment of benign prostatic hyperplasia (BPH) symptoms.

The approval is based on data from 2 randomised, double-blind, placebo-controlled, phase 3 trials lasting 12 weeks, and one 40-week open label study. In the 2 phase 3 studies, 923 patients (mean age 64.6 years) were randomised to receive either silodosin 8 mg QD or placebo.

Results from both trials showed that silodosin 8 mg QD for 12 weeks resulted in significant and rapid relief of BPH symptoms, compared with placebo, as measured by the International Prostate Symptom Score (IPSS). IPSS includes irritative and obstructive symptoms.

The most common drug-related side effect was retrograde ejaculation. Rates of discontinuing therapy due to retrograde ejaculation were low. The second most commonly-reported adverse event was dizziness. The incidence of treatment-related dizziness was low and only slightly higher in patients receiving silodosin compared with placebo-treated patients.

SOURCE Watson Pharmaceuticals, Inc.

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.